NEWS RELEASES
The information contained in each news release on this page was factually accurate on the date it was issued and posted.
Sutro ADC Effectively Targets Folate Receptor Alpha in Ovarian Cancer Preclinical Research
- Phase 1 Trial Planned for Late 2018 - Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate (ADC) to treat solid tumors was highly effective against ovarian cancer in...
Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies
Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 -- Two studies presented yesterday at the American Society of Hematology’s annual meeting in Atlanta showed frequent expression of CD74,...
Sutro Marks Two Drug Development Milestones
Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 -- Sutro Biopharma has received a manufacturing milestone payment from Celgene and has completed production of STRO-001, its first...
Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs
Will Rapidly Advance Promising Drug Candidates to the Clinic SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its 2014 immuno-oncology collaboration with Celgene on four programs that are advancing through preclinical...
New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts
STRO-001 Targets CD74, Eradicates B-Cell Hematologic Malignancy & Prolongs Survival A Powerful Attack on Multiple Myeloma & Lymphoma SOUTH SAN FRANCISCO, July 17, 2017 – STRO-001, Sutro Biopharma’s antibody drug conjugate targeting the CD74 cell surface...
Sutro Appoints Lobacki as Director; Leonard, Krishnan & Levy as Advisors
SOUTH SAN FRANCISCO, April 27, 2017 –Sutro Biopharma Inc. is adding an expert in drug commercialization to its board of directors, appointing clinical and scientific advisors and promoting a key executive as it moves closer to clinical development of STRO-001, an...
Sutro ADC Targeting CD74 Eradicates B-Cell Hematologic Malignancy, Prolongs Survival in Tumor Models
SOUTH SAN FRANCISCO, April 3, 2017 – STRO-001, an antibody drug conjugate developed by Sutro Biopharma Inc., demonstrated potent anti-tumor activity in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma tumor models while reducing the potential...
Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant Cell Lines and Animal Models of Non-Hodgkin Lymphoma and Multiple Myeloma
SOUTH SAN FRANCISCO, December 6, 2016 – Sutro Biopharma Inc. today announced that it has launched IND-enabling studies, including preparation for GLP toxicology, of STRO-001, an antibody drug conjugate, or ADC, that targets CD74, a protein highly expressed in B-cell...
Sutro ADCs Targeting CD74 Suppress Tumors in Multiple Malignant Cell Lines and Animal Models of Multiple Myeloma and Non-Hodgkin Lymphoma
SAN FRANCISCO, Sept. 19, 2016 -- Sutro Biopharma Inc. today announced that it has presented findings from two studies of investigational antibody drug conjugates, or ADCs, that it developed to target CD74, a protein highly expressed in hematologic malignancies. The...
Sutro Marks Important Progress — Receives Two Milestone Payments from Celgene
SAN FRANCISCO, Sept. 7, 2016 – Sutro Biopharma Inc. today announced that it has received two milestone payments from drug discovery and development partner Celgene Corporation (Celgene) for achievements in preclinical development and manufacturing under the company's...